MetaCap

Merck & Company Inc. Company Profile

NYSE: MRKHealth CareBiotechnology: Pharmaceutical PreparationsUSD

142.38-0.41 (-0.29%)

At close: Oct 8, 4:03 PM ET · Delayed 15 min

Merck at a glance

Merck & Company Inc. (NYSE: MRK) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Rahway, NJ. Merck is led by Mr. Robert M. Davis J.D. and employs about 73,000 people. At a market capitalization of $352.29 billion, it ranks among the largest companies in the US market.

MRK is a member of the SP500, DJIA. Its SEC Central Index Key (CIK) is 0000310158, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Merck do?

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Business description based on the company's public filings.

Company information

Legal name
Merck & Company Inc.
Ticker
NYSE: MRK
Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Robert M. Davis J.D.
Employees
73,000
Headquarters
126 East Lincoln Avenue, Rahway, NJ, United States
Phone
908 740 4000
Website
merck.com
Market cap
$352.29B
SEC CIK
0000310158
Latest annual report
10-K · Feb 24, 2026

Index membership

Companies similar to Merck

MRK peer companies
CompanyPrice% ChgMarket capCompare
NVSNovartis AG143.11-0.12%$272.01Bvs MRK
AZNAstraZeneca PLC158.78-0.84%$246.25Bvs MRK
ABBVAbbVie Inc.272.42+0.39%$481.40Bvs MRK
ABTAbbott Laboratories98.49-0.24%$170.43Bvs MRK
NVONovo Nordisk A/S38.18-0.21%$168.54Bvs MRK
PFEPfizer Inc.27.82-0.64%$158.56Bvs MRK
VRTXVertex Pharmaceuticals Incorporated503.25-0.47%$127.55Bvs MRK
BMYBristol-Myers Squibb Company59.58-0.20%$121.70Bvs MRK

Related